| Mrs Jessica Lonergan Tobin, LMHC | |
|
2974 E Main Rd, Portsmouth, RI 02871-4232 | |
| (401) 293-5790 | |
| (401) 293-5795 |
| Full Name | Mrs Jessica Lonergan Tobin |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 2974 E Main Rd, Portsmouth, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396103214 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | MHC00769 (Rhode Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jessica Lonergan Tobin, LMHC 2974 E Main Rd, Portsmouth, RI 02871-4232 Ph: (401) 293-5790 | Mrs Jessica Lonergan Tobin, LMHC 2974 E Main Rd, Portsmouth, RI 02871-4232 Ph: (401) 293-5790 |
News Archive
The advanced development of a novel next-generation anthrax vaccine and a new type of anthrax antitoxin have received support through new contracts funded the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority.
Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.
Doctors can use either an artery in the arm (the radial approach) or in the groin (the femoral approach) to safely perform percutaneous coronary intervention (PCI) on patients presenting with a heart attack, according to research presented at the American College of Cardiology's 68thAnnual Scientific Session. The research, which was stopped early, suggests the radial and femoral approach are equivalent in terms of the risk of death at 30 days.
Sanofi-aventis announced today the initiation of a multinational Phase III study evaluating the efficacy and safety of two doses of once daily teriflunomide (7mg or 14mg) versus placebo in patients with relapsing multiple sclerosis (RMS) treated with interferon beta (IFN beta).
› Verified 8 days ago
Daniel Erickson, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 98 Foxboro Ave, Portsmouth, RI 02871 Phone: 401-935-1074 | |
Ms. Jennifer Macdonald Dewolf, MSW, LICSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 2679 E Main Rd, Portsmouth, RI 02871 Phone: 401-935-3359 | |
Mrs. Jena Leigh Schmidt, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 107 Clock Tower Sq, Portsmouth, RI 02871 Phone: 401-683-7600 | |
Edward Joseph Ferreira, Counselor Medicare: Not Enrolled in Medicare Practice Location: 447 Bristol Ferry Rd, Portsmouth, RI 02871 Phone: 401-862-2553 | |
Patrick Golden, Counselor Medicare: Not Enrolled in Medicare Practice Location: 95 Maize Corn Rd, Portsmouth, RI 02871 Phone: 401-855-3475 | |
Ms. Brandi Sue Colesanti, M.A. LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 210 B Clock Tower Square, Portsmouth, RI 02871 Phone: 401-808-9388 | |
Elizabeth A. Walshe, LICSW Counselor Medicare: May Accept Medicare Assignments Practice Location: 26 Birch St, Portsmouth, RI 02871 Phone: 401-499-4331 |